Compare Redwire Corporation (RDW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs BIO-TECHNE Corp — how do they compare? Redwire Corporation trades at $9.58 (market cap $2.44B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 4.7× Redwire Corporation's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and BIO-TECHNE Corp for 64 Days on average.
| RDW | TECH | |
|---|---|---|
Market Cap | $2.44B | $11.36B |
Volume | 11,053,212 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $25.90 | $72.61 |
52-Week Low | $5.06 | $43.31 |
Typical Hold Time | 18 Days | 64 Days |
Enterprise Value | $1.97B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $9.57, down 6.54% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, though revenue growth remains strong at 89.6% year-over-year. Recent developments include a $980 million Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data center technology.
Despite strong analyst support (80% buy ratings) and a $14.88 price target suggesting 55% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents high-risk speculation on space infrastructure growth, dependent on successful execution and SpaceX's Starship development timeline.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
